GSA Capital Partners LLP Takes Position in Arvinas, Inc. $ARVN

GSA Capital Partners LLP bought a new position in shares of Arvinas, Inc. (NASDAQ:ARVN) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 142,214 shares of the company’s stock, valued at approximately $1,182,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Hussman Strategic Advisors Inc. bought a new stake in Arvinas in the fourth quarter valued at approximately $1,245,000. Brummer Multi Strategy AB bought a new position in Arvinas during the fourth quarter worth $1,973,000. VIRGINIA RETIREMENT SYSTEMS ET Al grew its stake in shares of Arvinas by 371.0% in the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 70,650 shares of the company’s stock valued at $838,000 after buying an additional 55,650 shares during the period. Armistice Capital LLC grew its stake in Arvinas by 50.0% in the fourth quarter. Armistice Capital LLC now owns 1,800,000 shares of the company’s stock valued at $21,348,000 after acquiring an additional 600,000 shares during the period. Finally, Public Employees Retirement System of Ohio grew its position in Arvinas by 876.1% in the 1st quarter. Public Employees Retirement System of Ohio now owns 97,611 shares of the company’s stock valued at $1,035,000 after purchasing an additional 87,611 shares during the period. 95.19% of the stock is owned by institutional investors and hedge funds.

Arvinas Stock Performance

Arvinas stock opened at $9.20 on Tuesday. The firm’s fifty day moving average price is $8.20 and its 200-day moving average price is $10.06. Arvinas, Inc. has a fifty-two week low of $6.95 and a fifty-two week high of $14.51. The stock has a market cap of $593.59 million, a P/E ratio of 92.01 and a beta of 1.71.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $2.95. The firm had revenue of $249.70 million during the quarter, compared to analysts’ expectations of $60.71 million. Arvinas had a return on equity of 1.91% and a net margin of 2.94%.The company’s revenue for the quarter was up 1014.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.84) EPS. On average, analysts predict that Arvinas, Inc. will post -0.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ARVN. Zacks Research raised Arvinas from a “hold” rating to a “strong-buy” rating in a report on Wednesday, August 5th. Citigroup lowered their price objective on shares of Arvinas from $24.00 to $21.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Wells Fargo & Company restated an “equal weight” rating and issued a $11.00 target price (down from $15.00) on shares of Arvinas in a research note on Tuesday, August 4th. Wedbush boosted their price target on shares of Arvinas from $11.00 to $12.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Finally, Stephens reissued an “overweight” rating and set a $18.00 price objective on shares of Arvinas in a report on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Arvinas presently has a consensus rating of “Hold” and a consensus target price of $14.17.

Insiders Place Their Bets

In other Arvinas news, CFO Andrew Saik sold 5,696 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $8.16, for a total value of $46,479.36. Following the completion of the sale, the chief financial officer directly owned 187,432 shares of the company’s stock, valued at $1,529,445.12. The trade was a 2.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.30% of the stock is owned by corporate insiders.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.